GYRE NASDAQ
Gyre Therapeutics, Inc.
1W: +5.8%
1M: -12.8%
3M: +15.8%
YTD: -4.1%
1Y: -20.1%
3Y: -12.9%
5Y: -87.3%
$6.53
+0.46 (+7.58%)
Weekly Expected Move ±6.0%
$5
$5
$6
$6
$7
Credit Risk of going bust: lower than 83% of companies Debt: 0.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.9%), Gyre Therapeutics, Inc. would be worth roughly what it owes.
Total debt $3.4M against a stock market value of $692.4M.
Distance to default 10.70 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 55.2%; Altman Z'' 4.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.9%), Gyre Therapeutics, Inc. would be worth roughly what it owes.
Total debt $3.4M against a stock market value of $692.4M.
Distance to default 10.70 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.7M (short-term plus half of long-term), stock volatility 55.2%; Altman Z'' 4.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
28 relationships28
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-05-23
Earliest Filing
2026-03-02
Latest Filing
partner: 18
target: 5
acquirer: 4
investor: 1
Counterparties (Filed by GYRE)
28 relationshipsCompanies named in GYRE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cullgen Inc. | — | target | Target company in an all-stock merger agreement valued at approximately $300 million. | 2026-03-02 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Open Market Sale Agreement | 2024-11-27 | View |
| Beijing Continent Pharmaceuticals Co., Ltd | — | target | Target company acquired by Catalyst Biosciences, Inc. (now Gyre Therapeutics, Inc.) in a business combination. | 2024-01-12 | View |
| Further Challenger International Limited | — | partner | Asset contributed by GNI USA to Gyre Therapeutics in exchange for common stock. | 2023-10-30 | View |
| Beijing Continent Pharmaceuticals Co., Ltd. | — | target | Target company acquired by Catalyst Biosciences (now Gyre Therapeutics) in the business combination. | 2023-10-30 | View |
| Continent Pharmaceuticals Inc. | — | partner | Partner in the business combination agreement with Gyre Therapeutics. | 2023-10-30 | View |
| Shanghai Genomics, Inc. | — | partner | Partner in the business combination agreement with Gyre Therapeutics. | 2023-10-30 | View |
| GNI Hong Kong Limited | — | partner | Partner in the business combination agreement with Gyre Therapeutics. | 2023-10-30 | View |
| GNI Group Ltd. | — | partner | Partner in the business combination agreement with Gyre Therapeutics. | 2023-10-30 | View |
| GNI USA, Inc. | — | investor | Invested in Gyre Therapeutics via a private placement of units consisting of convertible preferred stock and warrants. | 2023-10-30 | View |
| GNI Group Ltd. | — | partner | Contributor to the Business Combination Agreement | 2023-08-31 | View |
| GNI Hong Kong Limited | — | partner | Contributor to the Business Combination Agreement | 2023-08-31 | View |
| Shanghai Genomics, Inc. | — | partner | Contributor to the Business Combination Agreement | 2023-08-31 | View |
| Continent Pharmaceuticals Inc. | — | partner | Contributor to the Business Combination Agreement | 2023-08-31 | View |
| GNI USA, Inc. | — | partner | Contributor to the Business Combination Agreement | 2023-08-31 | View |
| GNI Hong Kong Limited | — | partner | Partnered with Catalyst in asset purchase and minority stockholder transactions | 2023-03-02 | View |
| Beijing Continent Pharmaceuticals Co., Ltd. | — | target | Target of GNI's acquisition of controlling interest alongside Catalyst | 2023-03-02 | View |
| GC Biopharma Corp. | — | acquirer | Acquired Catalyst's legacy rare bleeding disorder program assets for $6 million | 2023-03-02 | View |
| GNI Group Ltd. | — | partner | Partnered with Catalyst in asset purchase and minority stockholder transactions | 2023-03-02 | View |
| Vertex Pharmaceuticals Incorporated | VERX | partner | Counterparty in prior Asset Purchase Agreement referenced in CVR Agreement | 2022-12-27 | View |
| GNI Hong Kong Limited | — | acquirer | Seller of F351 Assets in Asset Purchase Agreement | 2022-12-27 | View |
| Further Challenger International Limited | — | partner | Entity contributing shares in Business Combination Agreement | 2022-12-27 | View |
| Continent Pharmaceuticals Inc. | — | partner | Target company in Business Combination Agreement | 2022-12-27 | View |
| Shanghai Genomics, Inc. | — | partner | Contributor of shares in Business Combination Agreement | 2022-12-27 | View |
| GNI USA, Inc. | — | partner | Contributor of shares in Business Combination Agreement | 2022-12-27 | View |
| GNI Group Ltd. | — | acquirer | Seller of F351 Assets in Asset Purchase Agreement | 2022-12-27 | View |
| Beijing Continent Pharmaceuticals Co., Ltd | — | target | Target company acquired indirectly in Business Combination Agreement | 2022-12-27 | View |
| Vertex Pharmaceuticals Incorporated | VRTX | acquirer | Acquired Catalyst Biosciences' complement portfolio and related intellectual property for $60 million in cash. | 2022-05-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-22 | Officer/Director Change; Exhibits | View | |
| 2026-09-01 | Regulation FD; Exhibits | View | |
| 2026-08-26 | Regulation FD; Exhibits | View | |
| 2026-08-07 | Earnings Release; Exhibits | View | |
| 2026-07-16 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-07-15 | Earnings Release; Exhibits | View | |
| 2026-06-16 | Shareholder Vote | View | |
| 2026-06-02 | Regulation FD; Exhibits | View | |
| 2026-05-14 | Regulation FD; Exhibits | View | |
| 2026-05-12 | Regulation FD; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-05-04 | Acquisition/Disposition; Unregistered Equity Sales; Officer/Director Change; Bylaws Amendment; Regul | Acquisition | View |
| 2026-04-17 | Material Agreement; Exhibits | Agreement | View |
| 2026-03-23 | Other Events | View | |
| 2026-03-12 | Regulation FD Disclosure | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-03-02 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
| 2026-01-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-10 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR